CStone Pharmaceuticals’ GAVRETO® Gains Inclusion in China’s National Reimbursement Drug List

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off CStone Pharmaceuticals ( (HK:2616) ) just unveiled an update. CStone Pharmaceuticals announced the inclusion of GAVRETO® (pralsetinib) in China’s National Reimbursement Drug List (NRDL), effective January 1, 2026. This inclusion marks a significant milestone for CStone, enhancing its market presence in Greater China and potentially increasing accessibility for patients with RET fusion-positive cancers. The drug, developed in collaboration with Blueprint Medicines, is already approved in several regions, including the U.S., Hong Kong, and Taiwan, for treating specific types of cancer, and this development is expected to strengthen CStone’s position in the oncology sector. The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page. More about CStone Pharmaceuticals CStone Pharmaceuticals, established in 2015 and listed on the Hong Kong Stock Exchange, is an innovation-driven biopharmaceutical company focused on developing therapies for oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications covering nine indications, with a pipeline featuring promising candidates such as antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines. Average Trading Volume: 15,662,792 Technical Sentiment Signal: Buy Current Market Cap: HK$8.24B